Study S000207

An Open-Label Extension Study of Protocol 2993-112 to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of AC2993 Given Two Times a Day to Subjects Treated With Metformin Alone

ClinicalTrials.gov record

Registration

Registration: NCT01789957
Study type: INTERVENTIONAL
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 225
Start: 2002-09
Primary completion: 2004-06
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:AC2993
Results posted: FALSE

Registered primary outcomes

Change in HbA1c from Day 1 of Protocol 2993-112 to Week 52 (or termination) [Day 1 of study 2993-112 through extension study termination (up to Week 52)]
Change in body weight from Day 1 of Protocol 2993-112 to Week 52 (or termination) [Day 1 of study 2993-112 through extension study termination (up to Week 52)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.